Pharma Journalist -

QIAGEN announced the expansion of its cell and gene therapy (CGT) portfolio with enhanced digital PCR (dPCR) solutions tailored for lentivirus-based applications. These solutions are…
Read More...

AbbVie announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This…
Read More...

Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric…
Read More...

Abeona Therapeutics Inc. announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel) gene-modified cellular…
Read More...

Merck, known as MSD outside the U.S. and Canada, has announced the start of construction on a $1 billion, 470,000-square-foot Biologics Center of Excellence in Wilmington, Delaware.…
Read More...

Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease…
Read More...

Biohaven Ltd. (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to…
Read More...

Debiopharm Research & Manufacturing S.A., a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services, a leading CRO…
Read More...

Repertoire Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, announced that it has entered into a…
Read More...

Granite Bio AG, a clinical-stage immunology company, has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant…
Read More...